Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Astellas' Prosidion Ltd. subsidiary granted Aestus exclusive, worldwide rights to develop
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury